FOG2 coding variant Ser657Gly is associated with Coronary Microvascular Disease through altered hypoxia-mediated gene transcription

Rationale: The coronary microvasculature is crucial for proper cardiac function, and coronary microvascular disease (CMVD) has emerged as an underdiagnosed and undertreated cause of ischemic heart disease. Friend of GATA 2 (FOG2) is a transcriptional co-regulator crucial for coronary development and the maintenance of the coronary microvasculature in adult mice. Little is known about the role of FOG2 in humans or its role in CMVD. Objective: Here, we report a genotype-first approach to determine the role of FOG2 in human coronary microvascular disease. Findings: We performed Phenome-Wide association studies and deep cardiac phenotyping through the Electronic Health record in patients with FOG2 coding variants and identified an association between rs28374544 (A1969G, S657G) and CMVD. Patients with S657G had increased chest pain, smaller burden of obstructive coronary artery disease, and altered coronary blood flow. Differential gene and pathway analysis using several genomic datasets showed that carriers of S657G have increased expression of genes involved in angiogenesis, glycolysis, and the hypoxia-inducible factor (HIF) pathway. In vitro functional studies show that FOG2 S657G promotes angiogenic gene expression and angiogenesis while decreasing oxygen consumption rate. FOG2 also regulates HIF1a occupancy of angiogenic genes. Conclusions: We identified a human missense variant which is associated with CMVD and established a potential mechanism by which the variant may altered angiogenic gene expression.

[1]  Yun S. Song,et al.  Whole-genome sequencing reveals a complex African population demographic history and signatures of local adaptation , 2023, Cell.

[2]  G. Sirugo,et al.  The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population , 2022, Journal of personalized medicine.

[3]  C. Yancy The Journey Toward Health Equity: Are We Nearing an Abyss or Ascending a Peak? , 2021, Circulation.

[4]  D. Mankoff,et al.  The role of resting myocardial blood flow and myocardial blood flow reserve as a predictor of major adverse cardiovascular outcomes , 2020, PloS one.

[5]  Swapan Mallick,et al.  Insights into human genetic variation and population history from 929 diverse genomes , 2019, Science.

[6]  F. F. Lunella,et al.  High mitogenic stimulation arrests angiogenesis , 2019, Nature Communications.

[7]  Akshay S. Desai,et al.  Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction , 2018, European heart journal.

[8]  Christopher D. Brown,et al.  Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. , 2017, Cell stem cell.

[9]  P. Libby,et al.  Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade , 2017, Circulation.

[10]  Pierre Tufféry,et al.  PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex , 2016, Nucleic Acids Res..

[11]  Ellen T. Gelfand,et al.  A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project , 2015, Biopreservation and biobanking.

[12]  W. Edwards,et al.  Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[13]  Euan A Ashley,et al.  RNA-Seq identifies novel myocardial gene expression signatures of heart failure. , 2015, Genomics.

[14]  S. Kelsey,et al.  TIMI Frame Count and Adverse Events in Women with No Obstructive Coronary Disease: A Pilot Study from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) , 2014, PloS one.

[15]  M. Broman,et al.  FOG-2 mediated recruitment of the NuRD complex regulates cardiomyocyte proliferation during heart development. , 2011, Developmental biology.

[16]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[17]  Erik Jørgensen,et al.  Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. , 2012, European heart journal.

[18]  S. Kong,et al.  Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart. , 2009, The Journal of clinical investigation.

[19]  F. Crea,et al.  Coronary microvascular dysfunction. , 2013, The New England journal of medicine.

[20]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Hirano,et al.  Novel cell lines derived from adult human ventricular cardiomyocytes. , 2005, Journal of molecular and cellular cardiology.

[22]  B. Dallapiccola,et al.  Mutations of ZFPM2/FOG2 gene in sporadic cases of tetralogy of Fallot , 2003, Human mutation.

[23]  R. Aikawa,et al.  Friend of GATA 2 Physically Interacts with Chicken Ovalbumin Upstream Promoter-TF2 (COUP-TF2) and COUP-TF3 and Represses COUP-TF2-dependent Activation of the Atrial Natriuretic Factor Promoter* , 2001, The Journal of Biological Chemistry.

[24]  S. Orkin,et al.  Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors. , 2001, Genes & development.

[25]  E. Svensson,et al.  A Functionally Conserved N-terminal Domain of the Friend of GATA-2 (FOG-2) Protein Represses GATA4-Dependent Transcription* , 2000, The Journal of Biological Chemistry.

[26]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.